Cited by 356interferon and immune responsesRNA regulation and diseaseRNA modifications and cancer

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L

Open access

Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., Kariko, K.·2011·Nucleic Acids Research

Open this paper in CoChat — free account Open PDF

Abstract

The interferon-induced enzymes 2'-5'-oligoadenylate synthetase (OAS) and RNase L are key components of innate immunity involved in sensory and effector functions following viral infections. Upon binding target RNA, OAS is activated to produce 2'-5'-linked oligoadenylates (2-5A) that activate RNase L, which then cleaves single-stranded self and non-self RNA. Modified nucleosides that are present in cellular transcripts have been shown to suppress activation of several RNA sensors. Here, we demonstrate that in vitro transcribed, unmodified RNA activates OAS, induces RNase L-mediated ribosomal RNA (rRNA) cleavage and is rapidly cleaved by RNase L. In contrast, RNA containing modified nucleosides activates OAS less efficiently and induces limited rRNA cleavage. Nucleoside modifications also make RNA resistant to cleavage by RNase L. Examining translation in RNase L(-/-) cells and mice confirmed that RNase L activity reduces translation of unmodified mRNA, which is not observed with modified mRNA. Additionally, mRNA containing the nucleoside modification pseudouridine is translated longer and has an extended half-life. The observation that modified nucleosides in RNA reduce 2-5A pathway activation joins OAS and RNase L to the list of RNA sensors and effectors whose functions are limited when RNA is modified, confirming the role of nucleoside modifications in suppressing immune recognition of RNA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/nar/gkr586

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citation
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Self-citation
2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members
Daffis, S., Szretter, K. J., Schriewer, J. M., Li, J., Youn, S., Errett, J. S., Lin, T., Schneller, S. W., Züst, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 910
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5
Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W., Ziebuhr, J., Szretter, K. J., Baker, S. C., Barchet, W., Diamond, M. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.1979 · Cited by 811
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Self-citation
Small self-RNA generated by RNase L amplifies antiviral innate immunity
Malathi, K., Dong, B., Gale, M., & Silverman, R. H. (2007) · Nature · doi:10.1038/nature06042 · Cited by 663
Modification and Editing of RNA
Auffinger, P., Grosjean, H., & Benne, R. (1998) · ASM Press eBooks · doi:10.1128/9781555818296 · Cited by 643
Pseudouridine in RNA: What, Where, How, and Why
Charette, M., & Gray, M. W. (2000) · IUBMB Life · doi:10.1080/152165400410182 · Cited by 577

Flagged first, then by citations

Show all 54 references

Research works printed but not linked: 2

2005, 23, 165
1995, 165, 233

Sorted by citations

Items 201–300 of 355

Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
Boros, G., Mikó, E., Muramatsu, H., Weissman, D., Emri, E., van der Horst, G. T. J., Szegedi, A., Horkay, I., Emri, G., Karikó, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131141 · Cited by 11
Expression, purification and characterization of the interferon-inducible, antiviral and tumour-suppressor protein, human RNase L
Gupta, A., & Rath, P. C. (2012) · Journal of Biosciences · doi:10.1007/s12038-011-9180-4 · Cited by 11
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
Córdoba, K. M., Jericó, D., Sampedro, A., Jiang, L., Iraburu, M. J., Martini, P. G. V., Berraondo, P., Avila, M. A., & Fontanellas, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.005 · Cited by 11
Vaccines on demand, part II: future reality
Geall, A. J., Kis, Z., & Ulmer, J. B. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2147501 · Cited by 10
N1-Methylpseudouridine directly modulates translation dynamics
Rozman, B., Broennimann, K., Rajan, K. S., Nachshon, A., Saha, C., Arazi, T., Mohan, V., Geiger, T., Wollner, C. J., Richner, J. M., et al. (2026) · Nature · doi:10.1038/s41586-025-09945-5 · Cited by 15
Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy
Tripathy, R. K., & Pande, A. H. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03829-z · Cited by 11
Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo
Xu, Y., Huang, L., Kirschman, J. L., Vanover, D. A., Tiwari, P. M., Santangelo, P. J., Shen, X., & Russell, D. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800924 · Cited by 10
Efficient Induction of Antigen-Specific CD8+ T-Cell Responses by Cationic Peptide-Based mRNA Nanoparticles
D’haese, S., Laeremans, T., den Roover, S., Allard, S. D., Vanham, G. L., & Aerts, J. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071387 · Cited by 10
Characteristics of the Cytotoxicity of Taraxacum mongolicum and Taraxacum formosanum in Human Breast Cancer Cells
Lin, C.-J., Chen, J.-T., Yeh, L.-J., Yang, R.-C., Huang, S., & Chen, T.-W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911918 · Cited by 10
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
Waghela, I. N., Mallory, K. L., Taylor, J. A., Schneider, C. G., Savransky, T., Janse, C. J., Lin, P. J. C., Tam, Y. K., Weissman, D., & Angov, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026052 · Cited by 10
Anticancer Effects ofTaraxacumvia Cell Cycle Arrest, Necrosis, Apoptosis, and Endoplasmic Reticulum Stress
Lin, C.-J., Liu, S.-T., Yang, R.-C., Wang, L.-H., Tsai, C.-C., Chen, T.-W., & Huang, S.-M. (2022) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x22500227 · Cited by 10
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
Therapeutic Application of mRNA for Genetic Diseases
Schürmann, P. J. L., Vriesman, S. V. B., Castro-Alpízar, J., Kooijmans, S. A. A., Nieuwenhuis, E. E. S., Schiffelers, R. M., & Fuchs, S. A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70019 · Cited by 9
N1-methylpseudouridine mRNA modification enhances efficiency and specificity of gene overexpression by preventing Prkra-mediated global translation repression
Lü, T., Chen, A., Li, C., Li, K., Wang, S., Zhang, Y., Yang, B., Wang, J., Gong, Q., Li, A., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf963 · Cited by 8
An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodents
Roier, S., Adamo, R., Rosini, R., Pezzicoli, A., Scarselli, M., Petsch, B., Jasny, E., & Rauch, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668937 · Cited by 8
Pseudouridylation-mediated gene expression modulation
Chen, J. L., Leeder, W. ‐., Morais, P., Adachi, H., & Yu, Y. (2024) · Biochemical Journal · doi:10.1042/bcj20230096 · Cited by 9
Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens
Sioud, M., Juzeniene, A., & Sæbøe‐Larssen, S. (2024) · Vaccines · doi:10.3390/vaccines12060624 · Cited by 10
Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells
Jain, A., Bataille, C. J. R., Milhas, S., Miller, A., Zhang, J., & Rabbitts, T. H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00857 · Cited by 8
LinearDesign: Efficient Algorithms for Optimized mRNA Sequence DesignPreprint
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020) · arXiv (Cornell University) · Cited by 8
Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approachPreprint
Liu, W., Alameh, M., Yang, J. F., Xu, J. R., Lin, P. J. C., Tam, Y. K., Weissman, D., & You, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.08.475499 · Cited by 8
Multisystem Endothelial Inflammation: A Key Driver of Adverse Events Following mRNA-Containing COVID-19 Vaccines
Szebeni, J., & Koller, Á. (2025) · Vaccines · doi:10.3390/vaccines13080855 · Cited by 11
Chemical Modifications in Nucleic Acid Therapeutics
Lennox, K. A., Young, R. C., & Behlke, M. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_3 · Cited by 8
RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials
Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7
Studies on interaction of oligoadenylates with proteins in vitro by MALDI-TOF mass spectrometry
Levchenko, S. M., Rebriev, A. V., Tkachuk, V. V., Dubey, L. V., Dubey, I. Y., & Tkachuk, Z. Y. (2013) · Biopolymers and Cell · doi:10.7124/bc.000804 · Cited by 7
Research progress on immune mechanism and control strategy of dsRNA impurities in mRNA vaccine
Liu, X., Hu, C., He, Q., Bai, Y., Zhang, X., Fu, Z., Ma, X., Xu, M., Liang, Z., & Mao, Q. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2510335 · Cited by 6
Immunological mechanisms of mRNA vaccines for infectious diseases
Locci, M., & Pardi, N. (2026) · Nature · doi:10.1038/s41586-026-10599-0 · Cited by 6
Bundling mRNA Strands to Prepare Nano‐Assemblies with Enhanced Stability Towards RNase for In Vivo Delivery
Yoshinaga, N., Cho, E., Koji, K., Mochida, Y., Naito, M., Osada, K., Kataoka, K., Cabral, H., & Uchida, S. (2019) · Angewandte Chemie · doi:10.1002/ange.201905203 · Cited by 6
Design, Synthesis, and Characterization of a Novel 2′–5′-Linked Amikacin-Binding Aptamer: An Experimental and MD Simulation Study
Mathivanan, J., Bai, Z., Chen, A. A., & Sheng, J. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00653 · Cited by 6
Enzymatic synthesis of RNA standards for mapping and quantifying RNA modifications in sequencing analysis
Gamper, H., McCormick, C. A., Makhamreh, A. K., Wanunu, M., Rouhanifard, S. H., & Hou, Y. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.04.024 · Cited by 6
Analyses of the 2023 Nobel Prize in Physiology or Medicine: Nucleoside Base Modifications and Effective mRNA Vaccines
Sterner, E. A. (2023) · Science & Technology Libraries · doi:10.1080/0194262x.2023.2292047 · Cited by 6
An oncolytic circular RNA therapy
Hamilton, A. G., & Mitchell, M. J. (2024) · Nature Cancer · doi:10.1038/s43018-023-00627-7 · Cited by 6
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
Lin, P. J. C., & Tam, Y. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00009-5 · Cited by 6
Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer
Moseman, J. E., Shim, D., Jeon, D., Rastogi, I., Schneider, K. M., & McNeel, D. G. (2025) · Vaccines · doi:10.3390/vaccines13090976 · Cited by 5
N4-Acetylcytidine enhances synthetic mRNA translation yield and fidelity
Schiffers, S., Nelson, B. D., Prigge, M. F., Krishna, S., Watkins, L., Zhu, Y., Tyagi, N., Beiki, H., Das, S., Raman, A. T., et al. (2026) · Nature · doi:10.1038/s41586-026-10729-8 · Cited by 5
Epigenetic Mechanisms in Osteoporosis: Exploring the Power of m6A RNA Modification
Tian, S., Song, Y., Guo, L., Hui, Z., Bai, M., & Miao, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70344 · Cited by 5
A review of advances in in vitro RNA preparation by ssRNAP
Shen, Y., Yang, D.-Q., Liu, Y., Lao, J.-E., Liu, C., Gao, X., He, Y.-R., & Xia, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141002 · Cited by 5
The Chemistry of Oligonucleotide Delivery
Rozema, D. B. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.07.003 · Cited by 5
The Essential Role of Double-Stranded RNA–Dependent Antiviral Signaling in the Degradation of Nonself Single-Stranded RNA in Nonimmune Cells
Kimura, S., Matsumiya, T., Shiba, Y., Nakanishi, M., Hayakari, R., Kawaguchi, S., Yoshida, H., & Imaizumi, T. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800456 · Cited by 5
Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells
Peterson, C. W., Venkataraman, R., Reddy, S. S., Pande, D., Enstrom, M., Radtke, S., Humbert, O., & Kiem, H. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.010 · Cited by 7
Future prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 7
Comparative analyses suggest a link between mRNA splicing, stability, and RNA covalent modifications in flowering plants
Palos, K. R., Dittrich, A. C. N., Lyons, E. H., Gregory, B. D., & Nelson, A. D. L. (2024) · BMC Plant Biology · doi:10.1186/s12870-024-05486-7 · Cited by 5
Optimization of CFTR-mRNA transfection in human nasal epithelial cells
Fernández, E. F., Bangel‐Ruland, N., Tomczak, K., & Weber, W.-M. (2016) · Translational Medicine Communications · doi:10.1186/s41231-016-0006-0 · Cited by 5
Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies
Hassan, M., Zalkifal, M., Wahab, A., Afzal, S., Rafique, S., Shahid, M., Khan, M. A., Ahmed, N., Idrees, M., & Shahıd, A. A. (2021) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2021038075 · Cited by 6
Synthesis of Long RNA with a Site-Specific Modification by Enzymatic Splint LigationPreprint
Gamper, H., McCormick, C. A., Tavakoli, S., Wanunu, M., Rouhanifard, S. H., & Hou, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.17.508400 · Cited by 5
Cross-competition shapes CD8+ T cell hierarchies and differentiation after RNA vaccinationPreprint
McCarron, M. J., Hornburg, M., Wu, T. D., Tong, A.-J., Tähtinen, S., Darwish, M., Freund, E. C., Feng, Y., Eisel, D., Balança, C.-C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.26.684631 · Cited by 5
siRNA-mediated therapeutic approaches improve acute kidney injury and limit its worsening
Wang, X., Huang, X., & Yang, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1697460 · Cited by 4
Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases
Castro-Alpízar, J., Lenderink, M. J., Nieuwenhuis, E. E. S., Kooijmans, S. A. A., & Fuchs, S. A. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109698 · Cited by 4
Harnessing mRNA technology for ischemic heart disease: a review of regenerative and protective therapies
Adjmi, M., Tse, I., & Zangi, L. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000118 · Cited by 4
In silico analysis of VEGFR2 and c-MET in consideration with immunologic facts: Implications for mRNA vaccine design against breast cancer
Ghayoumian, M., Shamsi, F., Madanchi, H., Ranjbar, M. M., Jalalirad, R., Sarrami‐Forooshani, R., & Mahdavi, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115315 · Cited by 4
Development of Trastuzumab-coupled, siRNA encapsulating mPolyplexes targeting HER2 overexpressing cancer cells
Müller, J. T., Caruso, S., Nguyen, A., Jürgens, D. C., Kromer, A. P. E., Sheshachala, S., Adams, N. B. P., & Merkel, O. M. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114904 · Cited by 4
Innate and adaptative immune mechanisms of COVID-19 vaccines. Serious adverse events associated with SARS-CoV-2 vaccination: A systematic review
Pallás, R. M. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.05.002 · Cited by 5
Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?
Tournier, J., & Kononchik, J. P. (2021) · Viruses · doi:10.3390/v13040569 · Cited by 6
Epitranscriptomics Markers Regulate the Infection by RNA Viruses
Stamatopoulou, V., & Zaravinos, A. (2021) · RNA technologies · doi:10.1007/978-3-030-71612-7_5 · Cited by 4
Mitigating Cellular Dysfunction by Addressing Contaminants in Synthetic circRNAPreprint
Zhang, Z., Li, W., Luo, D., Yuan, X., Yu, L., Wang, D., & Cao, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.613157 · Cited by 4
Chimeric hemagglutinin-based universal influenza mRNA vaccine induces protective immunity and bone marrow plasma cells in rhesus macaques
Styles, T. M., Akhtar, A., Gu, C., Neumann, G., Muramatsu, H., McPartlan, J. S., Talukder, P., Gratz, D., Stokdyk, K., Turner, H. L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102369 · Cited by 3
Engineered VPg saRNA achieves cap-independent, low-immunogenic and precise encoding of therapeutic proteins in vivo
Feng, Z., Chu, L., Li, Q., Zhou, J., Wu, P., Zhang, X., Pan, Y., Zou, J., Chen, Q., Xu, Z., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68364-w · Cited by 4
Critical applications and prospects of RNA modification in mRNA vaccines
Liu, C., Peng, J., Zhang, M., Xiang, H., & Yi, C. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0800 · Cited by 2
Watson‐Crick Base Pairing of N‐Methoxy‐1,3‐Oxazinane (MOANA) Nucleoside Analogues within Double‐Helical DNA
Afari, M. N. K., Nurmi, K., Virta, P., & Lönnberg, T. (2023) · ChemistryOpen · doi:10.1002/open.202300085 · Cited by 3
Airway-applied mRNA vaccine needs tailored sequence design and high standard purification that removes devastating dsRNA contaminant
Zhang, J., Li, C., Liu, Y., Liao, R., He, D., Xu, L., Chen, T., Xiao, Q., Luo, M., Chen, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.024 · Cited by 4
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v21 · Cited by 3
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5
Quantitative RNA pseudouridine landscape reveals dynamic modification patterns and evolutionary conservation across bacterial speciesPreprint
Xu, L., Shen, S., Zhang, Y., Guo, Z., Lu, B., Huang, J., Li, R., Shen, Y., Zhang, L., & Deng, X. (2025) · eLife · doi:10.7554/elife.107545 · Cited by 3
Quantitative RNA pseudouridine landscape reveals dynamic modification patterns and evolutionary conservation across bacterial species
Xu, L., Shen, S., Zhang, Y., Guo, Z., Lu, B., Huang, J., Li, R., Shen, Y., Zhang, L., & Deng, X. (2026) · eLife · doi:10.7554/elife.107545.3 · Cited by 2
Design strategies to optimize polymeric vectors for mRNA delivery
Turhan, Z. Y., Savaş, M., Alakbarov, A., & Bulmuş, V. (2025) · Journal of Macromolecular Science Part A · doi:10.1080/10601325.2025.2587806 · Cited by 2
A novel plasmid-based co-tethered transcription platform for high yield, high purity mRNA synthesis
Mala, P., Banerjee, R., Abek, A., Forster, J., Pinjari, A., Kulkarni, A. A., & Martin, C. T. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1355 · Cited by 2
Strategies to Improve the Stability and Translation of Therapeutic mRNAs
Gao, B., He, S., & Sun, Q. (2026) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100724-084241 · Cited by 3
A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics
Kukushkina-Zvezdova, A. A., Zherebtsova, A. A., Telegina, D. V., Skvortsov, I. A., Ivanov, R. A., & Reshetnikov, V. V. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08083-4 · Cited by 3
Detection of Base Modifications Using Long-Read Sequencing: Methods, Applications, and Challenges
Sheng, T., Wang, S., Xiao, Y., Ni, P., Zhu, Y., Zhong, Z., & Wang, J. (2026) · Big Data Mining and Analytics · doi:10.26599/bdma.2025.9020101 · Cited by 2
Mecanismos inmunitarios innatos y adaptativos de las vacunas COVID-19. Efectos adversos graves asociados a la vacunación contra el SARS-CoV-2: una revisión sistemática
Pallás, R. M. (2024) · Vacunas · doi:10.1016/j.vacun.2024.01.001 · Cited by 3
Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation
Geng, K., Rice-Boucher, P. J., Kashentseva, E. A., Dmitriev, I. P., Lu, Z. H., Goedegebuure, S. P., Gillanders, W. E., & Curiel, D. T. (2023) · Viruses · doi:10.3390/v15112277 · Cited by 3
“Goldilocks Modifications” for mRNA Therapeutics Won the Nobel Prize
Li, L. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0062 · Cited by 1
Decoding trends in mRNA vaccine research: A comprehensive bibliometric study
Zhang, C., Wang, Y., Peng, J., Wen, X., Zhang, Y., Li, K., Du, H., & Hu, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2355037 · Cited by 1
Codon Usage Bias Analysis of Citrus Leaf Blotch Virus
Ren, X., Xu, L., Yan, Y., Wang, Y., & Huang, A. (2025) · Viruses · doi:10.3390/v17111497 · Cited by 1
Nanopore direct RNA sequencing (DRS) of MS2 bacteriophages in E. coli throughout its life cycles reveals a complex transcriptional activity to control and maintain its growth
Ni, N., & Burgio, G. (2026) · Virology Journal · doi:10.1186/s12985-026-03121-5 · Cited by 1
Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation
Zhang, T., Peng, X., Qin, J., Zhu, B., Zhang, S., Deng, S., Song, Z., Han, Y., Zheng, H., Chen, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72025-3 · Cited by 1
mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions
Li, L., Wang, M., Ye, X., Liu, Z., Duan, Y., Chen, X., Ouyang, Y., Wu, Q., Sun, M., & Xie, T. (2026) · MedComm · doi:10.1002/mco2.70700 · Cited by 1
MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment
Saavedra, A. L., Díaz‐Chávez, J., Jiménez-Ríos, M. Á., & Scavuzzo, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847225 · Cited by 1
Nucleotides and nucleic acids; oligo‐ and polynucleotides
Loakes, D. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737708-00285 · Cited by 1
Adjuvants, the Elephant in the Room for RNA Vaccines
D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1
Promoter-independent synthesis of chemically modified RNA by human DNA polymerase θ variants
Tredinnick, T., Kent, T., Станиславович, М. Л., Li, Z., Madžo, J., Chen, X. S., & Pomerantz, R. T. (2023) · RNA · doi:10.1261/rna.079396.122 · Cited by 1
Comprehensive Review of the Initial 11 WHO Emergency Use Listed COVID-19 Vaccine Candidates: Mechanisms, Efficacy, and Comparative Attributes for Safety and Well-Being
Aditi, K., Kumari, N., Singh, P., Kumari, A., Deen, S. Y., & Kumar, R. (2023) · Microsphere · doi:10.59118/vqar2242 · Cited by 1
Pulmonary Delivery of Nucleic Acids
Conte, G., d’Angelo, I., Müller, J. T., Winkeljann, B., Carneiro, S. P., Merkel, O. M., & Ungaro, F. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-47567-2_5 · Cited by 1
Nobel Prize in physiology or medicine 2023: Development of mRNA therapeutics that paved the path of formulation of COVID-19 vaccine
Mandal, N. (2024) · Journal of Hematology and Allied Sciences · doi:10.25259/jhas_4_2024 · Cited by 1
The science of mRNA
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00003-0 · Cited by 1
Different Potential Vaccine Candidates of Covid-19 Diseases and their Immunological Aspect
Abebe, B. M. (2023) · Vaccines & Vaccination Open Access · doi:10.23880/vvoa-16000160
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-l393t-v35 · Cited by 1
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v30 · Cited by 1
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-l393t-v33 · Cited by 1
Airway applied IVT mRNA vaccine needs specific sequence design and high standard purification that removes devastating dsRNA contaminantPreprint
Zhang, J., Li, C., Liu, Y., Liao, R., He, D., Xu, L., Chen, T., Xiao, Q., Luo, M., Chen, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.22.614306 · Cited by 1
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2
Quantitative RNA pseudouridine landscape reveals dynamic modification patterns and evolutionary conservation across bacterial speciesPreprint
Xu, L., Shen, S., Zhang, Y., Guo, Z., Lu, B., Huang, J., Li, R., Shen, Y., Zhang, L., & Deng, X. (2026) · eLife · doi:10.7554/elife.107545.2 · Cited by 1
Delivery of Antiviral Nucleic Acids with Nonviral Vectors
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00005-3
Viral and bacterial sepsis: identification and characterization of cytokine profiles and cell death pathways
Paul, M. (2016) · Lu Zone Ul (Laurentian University)
Lipid nanoparticles for delivery of nucleic acid therapeutics
Chen, S. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0307282
New Genetic Approaches to Treating Diseases of the Skin
Hart, S. L., & Walker, A. (2019) · Wiley eBooks · doi:10.1002/9781119142812.ch170
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v32
Comprehensive characterization of viral transcriptomes using long-read sequencing
Moldován, N. (2020) · doi:10.14232/phd.10517
Aptamers for Detection and Diagnostics (ADD): Can mobile systems linked to biosensors support molecular diagnostics of SARS-CoV-2? Should molecular medicine explore multiple alternatives as adjuvants to or replacement for traditional and non-traditional vaccines?Preprint
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v35
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v31
Aptamers for Detection and Diagnostics (ADD): Can mobile systems process optical data from aptamer sensors to identify molecules indicating presence of SARS-CoV-2 virus? Should healthcare explore aptamers as drugs for prevention as well as its use as adjuvants with antibodies and vaccines?Preprint
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v33

Authors: Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K.
Affiliations: University of Pennsylvania (US)
Cleveland Clinic (US)
ORCID: Anderson, B. R.
Muramatsu, H.
Jha, B. K.
Silverman, R. H.
Weissman, D.
Venue: Nucleic Acids Research
Publisher: Oxford University Press (OUP)
Published: 2011-08-03
Volume: 39
Issue: 21
Pages: 9329-9338
ISSN: 0305-1048 (ISSN-L)
1362-4962
DOI: 10.1093/nar/gkr586
PMC: PMC3241635
OpenAlex: W2071136305
Cited by: 356
References: 54
Citations by year: 2026: 30 · 2025: 40 · 2024: 39 · 2023: 49 · 2022: 43 · 2021: 51 · 2020: 19 · 2019: 17 · 2018: 14 · 2017: 13 · 2016: 6 · 2015: 12 · 2014: 6 · 2013: 7 · 2012: 9
FWCI: 3.26
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/3.0 (vor, 1889 d)
Locations: Nucleic Acids Research (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Funders: National Institutes of Health (T32 GM- 07229)
National Heart, Lung, and Blood Institute (R42HL087688, R42HL87688)
National Cancer Institute (R01CA044059)
National Institute of General Medical Sciences (T32GM007229, T32GM07229)
National Institute of Allergy and Infectious Diseases (R01 AI50484, R01AI050484)
National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748, T32 DK-07748)
National Institute of Neurological Disorders and Stroke (R01NS029331)
National Institute of Dental and Craniofacial Research (R21DE019059)
National Center for Research Resources (T32RR007063)
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords: nucleoside modification, RNA, 2',5'-oligoadenylate synthetase, RNase L, pseudouridine, mRNA translation, mRNA stability, RNA sensors, innate immunity, interferon signaling, viral RNA sensing, immune evasion
MeSH terms: Animals, Cells, Cultured, Endoribonucleases, Half-Life, Humans, Nucleosides, Pseudouridine, RNA, RNA, Ribosomal, Protein Biosynthesis, Uridine, 2',5'-Oligoadenylate Synthetase, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks